Insmed Incorporated
Trade Insmed Incorporated 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About INSM
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline.
INSM Key Statistics
Stock Snapshot
With a market cap of 37.53B, Insmed Incorporated(INSM) trades at $177.00. The stock has a price-to-earnings ratio of -28.47.
During the trading session on 2026-01-12, Insmed Incorporated(INSM) shares reached a daily high of $177.00 and a low of $177.00. At a current price of $177.00, the stock is 0.0% higher than the low and still 0.0% under the high.
Trading volume for Insmed Incorporated(INSM) stock has reached 1.81K, versus its average volume of 2.31M.
The stock's 52-week range extends from a low of $60.40 to a high of $212.75.
The stock's 52-week range extends from a low of $60.40 to a high of $212.75.
INSM News
Insmed Inc (NASDAQ:INSM) on Friday outlined a commercial and clinical roadmap for 2026, highlighting strong momentum from its respiratory portfolio and a series...
In early trading on Friday, shares of Insmed topped the list of the day's best performing components of the Nasdaq 100 index, trading up 4.9%. Year to date, Ins...
Claim 70% Off TipRanks Premium Insmed ( (INSM) ) has shared an announcement. On January 9, 2026, Insmed reported strong preliminary unaudited 2025 financial r...
Analyst ratings
95%
of 20 ratingsMore INSM News
Insmed (INSM) plans to launch Brinsupriin the European Union in the first half of 2026. Insmed anticipates commercial launches in the United Kingdom and Japan i...
New insider activity at Insmed ( (INSM) ) has taken place on January 8, 2026. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing...
Morgan Stanley analyst Maxwell Skor lowered the firm’s price target on Insmed (INSM) to $157 from $158 and keeps an Equal Weight rating on the shares. The firm...
If you are wondering whether Insmed's share price still lines up with its fundamentals, you are not alone; this article will walk through what the current valua...
UBS analyst lowered the firm’s price target on Insmed (INSM) to $215 from $223 and keeps a Buy rating on the shares. The Biotech sector enters 2026 on a cautiou...